Navigation Links
New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation
Date:7/6/2009

ation through 7 days post-treatment with the approved ablation catheters. The study will also collect data on long term safety (adverse events) data, such as death, stroke, myocardial infarction, clinically manifested pulmonary vein stenosis, etc., at 5 years post-treatment. The second PAS is a subgroup analysis from an ongoing larger study that will look at the incidence of stroke, and compare the 3-year incidence of stroke between patients treated with the approved ablation catheters versus patients treated with medication. This study will analyze total mortality, serious bleeding and cardiac arrest.

Also, last week, the FDA approved a new medication, dronedarone, for treatment of atrial fibrillation. For more information go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170276.htm.

AHRQ's new report, Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation, is the newest analysis from the Agency's Effective Health Care program. That program, authorized by the Medicare Prescription Drug, Improvement, and Modernization Act, represents an important federal effort to compare alternative treatments for health conditions and make the findings public. The program is intended to help patients, doctors, nurses, and others choose the most effective treatments. Information, including the new report, can be found at http://www.effectivehealthcare.ahrq.gov.

Editor's Note: Use Twitter to get AHRQ news updates: www.twitter.com/ahrqnews.


'/>"/>
SOURCE Agency for Healthcare Research & Quality
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... . , Reactive ... mode of action is complex: In low concentrations they ... at high concentrations they can cause "oxidative stress", which ... signaling unfolds in single cells and organelles in real-time, ... by the teams of LMU Professor Martin Kerschensteiner and ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2
... than in for-profit residences, review finds , WEDNESDAY, Aug. ... care than for-profit facilities, say Canadian researchers who reviewed ... , Forty studies found that non-profit nursing homes provided ... for-profit homes delivered better care. The remaining studies had ...
... , , FRIENDSWOOD, Texas, Aug. ... develops, manages and owns faith-based senior living facilities, today announced the ... development of a new senior living facility in the Houston, Texas ... $10 million senior living facility in Katy, Texas, should be available ...
... , , , NASHVILLE, ... payment cycle management solutions, today announced the implementation of its ... Group. The Sentinel Group, a recognized leader in healthcare fraud ... 5, 2009. , , The Sentinel ...
... NANJING, China, Aug. 5 /PRNewswire-Asia/ -- ... manufacturer and supplier of branded generic and,innovative anti-cancer pharmaceuticals ... 2009 second quarter results on Monday, August 17, 2009,after ... executive,officer, Jinsheng Ren, and chief financial officer, Frank Zhigang ...
... INDIANAPOLIS, Aug. 5 In the midst of the down economy, ... worse - forcing them to make difficult sacrifices to afford medications ... On Aug. 1, 2009, Lilly USA adjusted the income ... enrollment of eligible patients with incomes at or less than 300 ...
... , HACKENSACK, N.J., Aug 5 ReGen Biologics, a ... regarding its Menaflex collagen meniscus implant that were made in a ... party unaffiliated with the company. ReGen was unaware of ... on the Internet. The statements made in the release do ...
Cached Medicine News:Health News:Not-For-Profit Nursing Homes Fare Better in Studies 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 2Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 4Health News:Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 3Health News:ReGen Biologics Clarifies Recent Press about the Menaflex Device 2
Acetate Plate Sealers 100/Box...
... Microseal 'B' seals provide an adhesive-based sealing ... The aggressive adhesive layer ensures secure sample ... and tight sealing during thermal cycling when ... lid. The perforated end-tabs can be removed ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Inquire...
Medicine Products: